Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 121 Melanoma 111 Neoplasms 66 Carcinoma, Renal Cell 60 Colorectal Neoplasms 43 Neoplasm Metastasis 39 Squamous Cell Carcinoma of Head and Neck 36 Stomach Neoplasms 35 Carcinoma, Hepatocellular 33 Carcinoma, Transitional Cell 27 Lung Neoplasms 23 Pancreatic Neoplasms 22 Triple Negative Breast Neoplasms 21 Ovarian Neoplasms 21 Head and Neck Neoplasms 21 Advanced Cancer 19 Breast Neoplasms 17 Urinary Bladder Neoplasms 15 Small Cell Lung Carcinoma 14 Kidney Neoplasms 13 Recurrence 11 Hodgkin Disease 11 Uterine Cervical Neoplasms 10 Skin Neoplasms 10 Lymphoma 10 Solid Tumor 9 Mesothelioma 9 Endometrial Neoplasms 9 Carcinoma, Merkel Cell 9 Carcinoma 9

Interventions

pembrolizumab 3 relatlimab 1 lifileucel 1 dabrafenib 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Melanoma, Cutaneous Malignant × Nivolumab × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡